explore -WSS

explore

author：leisure time 2025-08-11 08:00:31 - browse：46

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Community Health Systems hospitals under DOJ investigation

focus

WSS

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

A solution to the after

Flu vaccine offering decent levels of protection this winter, new data show

The Harvard botanist who searched for psychedelics in the Amazon

In search for therapies for solid tumors, companies turn to claudin

Wikipedia

explore

hotspot

In Memoriam: Notable people who died in 2023

Clinical trials giant ICON acquires HumanFirst

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How to fix the rural physician shortage in the U.S.

As demand for Covid shots wanes, Moderna seeks its next success

Pfizer highlights cancer drugs it thinks could reignite investor interest

Duchenne breakthrough therapy leaves behind pioneering families

Alabama hospital puts IVF treatments on hold

Peter Hotez and the public health issue of online harassment

He's a Nobel laureate. Critics say he was misleading on Covid

explore

With competition flaring, obesity drug hits goal in liver disease study

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Alabama frozen embryo ruling has major implications for IVF clinics

FDA does about

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Clinical trials giant ICON acquires HumanFirst

leisure time

knowledge

focus

knowledge